Dergiler / Erciyes Medical Journal / 2016 / Cilt: 38 - Sayı: 4

We Perform Vasoreactivity Test in Pulmonary Hypertension, but Reproducibility?

Sayfa
153–154
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

We presented a case in this article whose vasoreactivity test was positive initially, but negative in follow-up

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Sarcoidosis is a chronic, granulomatous disease that it can affect all organs.
📊
Temel Bulgular & Veri:PH is determined by right cardiac catheterization and mean pulmonary artery pressure is >=25 mmHg at rest.
💡
Sonuç & Katkı:We presented a case in this article whose vasoreactivity test was positive initially, but negative in follow-up
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Sarcoidosis is a chronic, granulomatous disease that it can affect all organs. Pulmonary hypertension (PH) is one of the most important complications of sarcoidosis and indicates poor prognosis. PH is determined by right cardiac catheterization and mean pulmonary artery pressure is >=25 mmHg at rest. Vasoreactivity test is recommended to this patients, to determine vasodilator drugs to response of pulmonary vascular bed. Calcium channel blockers are used in patients with a positive test vasoreactivity. We presented a case in this article whose vasoreactivity test was positive initially, but negative in follow-up

🔖

Bu Makaleye Atıf Yap

ÖZKEÇECİ, G., AKÇİ, Ö., ONRAT, E., AVŞAR, A. (2016). We Perform Vasoreactivity Test in Pulmonary Hypertension, but Reproducibility?. Erciyes Medical Journal, Cilt: 38 - Sayı: 4, 153–154. https://ajindex.com/articles/223495

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (3)

  1. Judson MA. The Clinical Features of Sarcoidosis: A Comprehensive Review Clinic Rev Allerg Immunol 2015; 49: 63
  2. Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010; 138: 1078-85. [CrossRef] 3. Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hyperten-sion in advanced sarcoidosis: Epidemiology and clinical characteristics. Eur Respir J 2005; 25(5): 783-8. [CrossRef] 4. Galie` N, Hoeper MM, Humbert M, Torbicki A, Vachiery J, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pul-monary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the Interna-tional Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30(20): 2493-537. [CrossRef] 5. Sompradeekul S, Wattanasiriphakdee S. Hemodynamic effect of ilo-prost inhalation and oral sildenafil during acute vasoreactivity test in pulmonary arterialhypertension J Med Assoc Thai 2015; 98(2): 144-9
  3. Elkiran O, Karakurt C, Koçak G. Combined effect of aerosolized iloprost and oxygen on assessment of pulmonary vasoreactivity in children withpulmonary hypertension. Anadolu Kardiyol Derg 2014; 14(4): 383-88. [CrossRef] 7. Sitbon O, Humbert M, Jaïs X, Ioos V, Hamid AM, Provencher S, et al. Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension. Circulation 2005; 111(23): 3105-11. [CrossRef] 8. Fisher KA, Serlin DM, Wilson KC, Walter RE, Berman JS, Farber HW. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 2006; 130(5): 1481-8. [CrossRef] 9. Milman N, Burton CM, Iversen M, Videbaek R, Jensen CV, Carlsen J. Pulmonary hypertension in end-stage pulmonary sarcoidosis: ther-apeutic effect of sildenafil? J Heart Lung Transplant 2008; 27(23): 329-34. [CrossRef] 10. Baughman RP, Culver DA, Cordova FC, Padilla M, Gibson KF, Lower EE, et al. Bosentan for sarcoidosis-associated pulmonary hyperten-sion: a double-blind placebo controlled randomized trial. Chest 2014; 145(4): 810-7. [CrossRef]